According to GlobalData’s medical device pipeline database, 99 Transcatheter Aortic Valve Replacement (TAVR) devices are in various stages of development globally. GlobalData’s report Transcatheter Aortic Valve Replacement (TAVR) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 65 are in active development, while the remaining 36 are in an inactive stage of development. There are 25 products in the early stages of development, and the remaining 40 are in the late stages of development.

Transcatheter Aortic Valve Replacement (TAVR), also known as, Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive procedure used to treat severe aortic valve stenosis by implanting a Transcatheter Heart Valve in a patient’s diseased aortic valve. The procedure is largely performed transfemorally (through the groin) but can also be performed via alternative pathways including the transapical, transaortic, transcarotid, transsubclavian and transcaval approaches. One unit refers to one Transcatheter Aortic Valve.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Transcatheter Aortic Valve Replacement (TAVR) pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Transcatheter Aortic Valve Replacement (TAVR) devices. Overall, most of these Transcatheter Aortic Valve Replacement (TAVR) pipeline devices are being developed by private entities.

Key players involved in the active development of Transcatheter Aortic Valve Replacement (TAVR) include Boston Scientific, Venus Medtech Hangzhou, Symetis, Colibri Heart Valve, Edwards Lifesciences, MicroPort CardioFlow Medtech, NewMed Medical, Peijia Medical, Lepu Medical Technology (Beijing) and JC Medical.

For a complete picture of the developmental pipeline for Transcatheter Aortic Valve Replacement (TAVR) devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.